INCY Stock Chart & Stats
$2036.00
$30.00(1.50%)
At close: 4:00 PM EDT
$2036.00
$30.00(1.50%)
Day’s Range― - ―
52-Week Range$1,301.04 - $2,373.80
Previous CloseN/A
Volume9.71K
Average Volume (3M)18.00
Market Cap
$434.51B
Enterprise Value$19.11K
Total Cash (Recent Filing)$4.54B
Total Debt (Recent Filing)$38.27M
Price to Earnings (P/E)15.3
Beta0.12
Next Earnings
Nov 03, 2026EPS Estimate
-48.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.13
Shares Outstanding202,697,740
10 Day Avg. Volume0
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,210.29Price Target Upside8.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)63.87
Revenue Forecast (FY)$100.79B
Bulls Say, Bears Say
Bulls Say
Broad Commercial GrowthUnderlying growth remains strong even after removing the settlement benefit, with core products expanding beyond the established Jakafi franchise. This broadens the revenue base, reduces dependence on a single therapy, and supports sustained investment in commercialization and research.
Strong Cash Generation And Low LeverageMinimal leverage and substantial free cash flow give Incyte considerable flexibility to fund clinical development, business development, and shareholder priorities internally. This financial capacity lowers balance-sheet risk and allows the company to pursue growth opportunities through changing biotech cycles.
Late-stage Pipeline ExpansionAdding a Phase 3 hematology asset expands Incyte beyond its existing oncology and inflammation programs and increases the number of potential future growth drivers. The transaction also adds a differentiated monthly dosing opportunity, although clinical and regulatory execution remain necessary.
Bears Say
One-time Benefit Clouds Earnings QualityThe settlement improves reported results but does not represent recurring product demand or ongoing cash economics. Investors must therefore separate underlying commercial growth from the temporary accounting benefit, making near-term revenue and margin trends less representative of normalized performance.
Elevated Investment BurdenThe acquisition-related charge and increased late-stage spending create a substantial near-term expense burden that can compress reported profitability and cash flow. These investments may strengthen the portfolio, but returns depend on successful development, approvals, and eventual commercial adoption.
Pipeline Setback In JAK2 ProgramEnding the 058 program removes a near-term JAK2 V617F development option and narrows Incyte’s path in that target area. The company must rely more heavily on next-generation programs and external opportunities, extending timelines and increasing execution dependence for future pipeline value.
Incyte News
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $1301.04 and its highest was $2373.80 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $434.51B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Nov 03, 2026 which is in 54 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Jul 28, 2026. The company reported $52.537 earnings per share for the quarter, beating the consensus estimate of $37.337 by $15.2.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is -48.08.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 202,697,740 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $52.537 in its last earnings report, beating expectations of $37.337. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in MX:INCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,210.29 (8.56% Upside)
$2,210.29 (8.56% Upside)
Blogger Sentiment
Bullish
MX:INCY Sentiment 82%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $313.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Incyte Corp
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline maturation: double-digit and multi-factor sales growth (notably Opzelura and core products), multiple regulatory milestones and new Phase III starts, a strategic acquisition adding a high-potential hematology asset, and an upward revision to full-year revenue guidance. Offsetting these positives are reliance on a one-time CMS settlement that materially boosted near-term results and guidance, the discontinuation of the 058 JAK2 program, and materially higher near-term operating expenses driven by acquisition-related charges and expanded late-stage investments. Management emphasized execution risk, reimbursement dynamics and regulatory discussions that remain unresolved for some programs. Overall, the highlights — broad commercial growth, pipeline progression and strengthened late-stage portfolio — outweigh the lowlights, though near-term margin and execution risks merit monitoring.View all MX:INCY earnings summariesINCY Revenue Breakdown
84.69% Product revenues, net
12.39% Product royalty revenues
2.92% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$2,210.29
▲(8.56% Upside)